Cargando…
High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study
BACKGROUND: Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease characterized by inflammation of the interlobular bile ducts. Ursodeoxycholic acid (UDCA) is the only FDA approved first-line therapy for PBC, but up to 40% of patients with PBC have an incomplete response to UDCA....
Autores principales: | Zhu, Huiling, Zheng, Mengyao, He, Haiyu, Lei, Hongtao, Tai, Wenlin, Yang, Jinhui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657125/ https://www.ncbi.nlm.nih.gov/pubmed/37978445 http://dx.doi.org/10.1186/s12876-023-03031-8 |
Ejemplares similares
-
Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis
por: Shu, Yanyun, et al.
Publicado: (2021) -
External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: Cheung, Angela C., et al.
Publicado: (2018) -
Diagnostic and Prognostic Value of Monocyte-to-Lymphocyte Ratio and Red Cell Distribution Width to Lymphocyte Ratio in Primary Biliary Cholangitis
por: Jiang, Yanting, et al.
Publicado: (2023) -
Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study
por: Cançado, Guilherme Grossi Lopes, et al.
Publicado: (2022) -
Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
por: Alomari, Mohammad, et al.
Publicado: (2019)